The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Accolate (zafirlukast) has been approved for the preventative
and chronic treatment of asthma in adults and children 12 years of
age and older.
Accolate has been studied in more than 4,000 people worldwide.
In clinical trials in patients with mild to moderate asthma,
Accolate was shown to improve lung function and reduce daytime and
nighttime asthma symptoms.
Mechanism of Action
Accolate is the first leukotrine receptor antagonist, a new
class of drugs, to receive FDA clearance. Accolate works by
blocking the effect of leukotrines, natural substances in the body
that can contribute to asthma symptoms.
More than 12 million Americans suffer from asthma, and worldwide
more than 100 million people have this chronic lung disease.